secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2022-07-15T23:59:59+00:00
Accession:  0000950142-22-002215
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Dr. Keith Harris and Dr. Fahed Al Marzooqi to board
-----------------------------------------------------------------------------

- Dr. Keith Harris appointed as Board member and chair of Audit Committee; Dr. Fahed Al Marzooqi appointed as Board member.
- Dr. Harris is a London-based investment banker with 30-year career at Morgan Grenfell, Drexel Burnham, Apax, and HSBC.
- Dr. Al Marzooqi is COO of G42 Healthcare; his appointment follows the May 2022 stock purchase agreement with G42 Investments.
- Each new director receives $35k annual cash, 25,000 options upon appointment, plus 25,000 options in annual equity grants.
- Dr. Harris qualifies as independent and as an audit committee financial expert under SEC rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222002215/0000950142-22-002215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222002215/eh220270165_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-002215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer